United States Health Care Reform: Progress to Date and Next Steps

SXU Addresses the Nursing Shortage with its BSN and ABSN Programs

Retrieved on: 
Tuesday, March 14, 2023

SXU's nursing programs prepare students for success with mentorship from expert clinical faculty who are knowledgeable about the complexities of the health care system.

Key Points: 
  • SXU's nursing programs prepare students for success with mentorship from expert clinical faculty who are knowledgeable about the complexities of the health care system.
  • SXU also offers an MSN in nursing education so we can continue to add nursing instructors to the population," Fitzgerald said.
  • The Online Accelerated Bachelor of Science in Nursing (ABSN) Program at SXU: Putting Students into the Nursing Field Sooner
    With an accelerated Bachelor of Science in Nursing (ABSN) option, students can finish their nursing degree in just 15 months, so they can get started in the field sooner.
  • For more information on SXU's nursing programs, visit the School of Nursing and Health Sciences (SONHS) webpage .

Axsome Therapeutics, Inc. Investor News: Robbins LLP is Investigating Axsome Therapeutics, Inc. (AXSM) on Behalf of Shareholders

Retrieved on: 
Wednesday, June 1, 2022

Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.

Key Points: 
  • Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.
  • If you would like more information about our investigation of Axsome Therapeutics, Inc.'s misconduct, click here .
  • However, unbeknownst to investors, the Companys preparation and eventual submission of the AXS-07 NDA was plagued with chemistry, manufacturing, and control (CMC) issues.
  • Then, on April 25, 2022, Axsome disclosed in an SEC filing that, [o]n April 22, 2022, Axsome .

AXSM Shareholder News: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Axsome Therapeutics, Inc. (AXSM)

Retrieved on: 
Wednesday, May 25, 2022

Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.

Key Points: 
  • Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.
  • However, unbeknownst to investors, the Companys preparation and eventual submission of the AXS-07 NDA was plagued with chemistry, manufacturing, and control (CMC) issues.
  • Then, on April 25, 2022, Axsome disclosed in an SEC filing that, [o]n April 22, 2022, Axsome .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

AXSM Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Axsome Therapeutics, Inc. (AXSM)

Retrieved on: 
Friday, May 20, 2022

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Axsome Therapeutics, Inc. (NASDAQ: AXSM) securities between December 20, 2019 and April 22, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Axsome Therapeutics, Inc. (NASDAQ: AXSM) securities between December 20, 2019 and April 22, 2022, for violations of the Securities Exchange Act of 1934.
  • Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.
  • What is this Case About: Axsome Therapeutics, Inc. (AXSM) Made Misleading Statements in Connection with its New Drug Application for AXS-07 for the Acute Treatment of Migraine.
  • Then, on April 25, 2022, Axsome disclosed in an SEC filing that, [o]n April 22, 2022, Axsome .

Shareholder Alert: Did You Purchase Shares of Axsome Therapeutics, Inc. (AXSM)? Robbins LLP Alerts Investors of Class Action Against Axsome Therapeutics, Inc.

Retrieved on: 
Wednesday, May 18, 2022

Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.

Key Points: 
  • Axsome is a biopharmaceutical company that develops novel therapies for central nervous system ("CNS") disorders in the U.S.
  • If you would like more information about Axsome Therapeutics, Inc.'s misconduct, click here .
  • However, unbeknownst to investors, the Companys preparation and eventual submission of the AXS-07 NDA was plagued with chemistry, manufacturing, and control (CMC) issues.
  • Then, on April 25, 2022, Axsome disclosed in an SEC filing that, [o]n April 22, 2022, Axsome .

Marki Flannery is appointed to CareConnect Advisory Board

Retrieved on: 
Tuesday, November 23, 2021

PORT WASHINGTON, N.Y., Nov. 23, 2021 /PRNewswire/ -- Home Care technology provider, CareConnect is pleased to announce that Marki Flannery has joined their Advisory Board and will provide consulting services.

Key Points: 
  • PORT WASHINGTON, N.Y., Nov. 23, 2021 /PRNewswire/ -- Home Care technology provider, CareConnect is pleased to announce that Marki Flannery has joined their Advisory Board and will provide consulting services.
  • Following her retirement from VNSNY, Marki was appointed to the Pace University Board ofTrustees,where she serves onseveralcommittees.Ms.
  • "We are so excited to have Marki on our Advisory Board," confirmed Michael Gelman, President and COO CareConnect.
  • Marki is a frequent presenter at state and national conferences and has held board leadership positions in several industry associations.

SCAN Group Announces Formation of Diversification Advisory Council

Retrieved on: 
Monday, October 18, 2021

SCAN Group, whose holdings include SCAN Health Plan , one of the nations largest not-for-profit Medicare Advantage plans, has tapped luminaries from the worlds of medicine, finance, technology and government for its Diversification Advisory Council.

Key Points: 
  • SCAN Group, whose holdings include SCAN Health Plan , one of the nations largest not-for-profit Medicare Advantage plans, has tapped luminaries from the worlds of medicine, finance, technology and government for its Diversification Advisory Council.
  • The expert advisory council weve built will bring decades of experience to bear in support of that agenda.
  • The inaugural members of SCANs Diversification Advisory Council include:
    Executive chairman, Health Evolution and former managing partner at HEP, a fund that invested in companies with the potential to transform health care delivery.
  • The formation of the Diversification Advisory Council comes as SCAN accelerates its overall diversification and expansion efforts.

Equality Health Appoints Andy Slavitt to Board of Directors

Retrieved on: 
Thursday, September 30, 2021

"We're excited to welcome Andy to our board during a time of significant growth and changeboth for Equality Health and the healthcare system as a whole," said Hugh Lytle, founder and chief executive officer of Equality Health.

Key Points: 
  • "We're excited to welcome Andy to our board during a time of significant growth and changeboth for Equality Health and the healthcare system as a whole," said Hugh Lytle, founder and chief executive officer of Equality Health.
  • He is currently board chair of United States of Care, a national non-profit health advocacy organization he founded.
  • He is a Distinguished Health Policy Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania.
  • For more information about Equality Health, visit www.equalityhealth.com or follow @EqualityHealth on Facebook, @EqualityHealth on Twitter, and @EqualityHealth on LinkedIn.